TG Therapeutics (TGTX) Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $161.7 million, a 93% increase year-over-year and a 15% increase sequentially.

Product Revenue: $159.3 million, primarily driven by U.S. BRIUMVI net sales of $152.9 million.

GAAP Net Income: $390.9 million ($2.43 per diluted share), significantly up from $3.9 million ($0.02 per diluted share) in Q3 2024, largely due to a nonrecurring tax benefit of $365 million from the release of a deferred tax asset valuation allowance.

Operating Expenses: Approximately $86.6 million for Q3, up from $71 million in Q2 2025, but on track to meet full-year guidance of $300 million to $320 million.

Cash Position: Ended Q3 with approximately $178 million in cash and equivalents after completing a $100 million share repurchase program.

2Strategic Updates and Business Highlights

BRIUMVI Performance: Continued strong demand with net sales exceeding internal targets and market expectations. The drug is positioned as a best-in-class treatment for relapsing MS.

Clinical Development: Two pivotal studies launched:

ENHANCE: Aiming to simplify BRIUMVI dosing to a single day 1 infusion, with enrollment completed and data expected mid-2026.

Subcutaneous Ublituximab: Aiming to create a self-administered version, with enrollment expected to finish in H1 2026 and potential approval in 2028.

Market Expansion: Focus on expanding the commercial field organization, particularly in hospitals, and enhancing patient engagement through a national television campaign.

3Forward Guidance and Outlook

Revenue Guidance: Increased full-year 2025 U.S. BRIUMVI net revenue guidance from $570 million to approximately $585 million, reflecting strong year-to-date performance and demand trends.

Long-term Potential: Confidence in BRIUMVI becoming a multibillion-dollar brand, with expectations for continued growth driven by new patient acquisition and retention.

4Bad News, Challenges, or Points of Concern

Market Dynamics: Some concerns about potential slowing growth in Q4 compared to previous years, with expectations of a 14% quarter-over-quarter increase.

Competitive Pressures: The subcutaneous market segment is growing, with existing competitors gaining traction, which could impact BRIUMVI's market share.

Investment Caution: The company has been selective in pursuing business development opportunities, indicating a high bar for ROI which may limit expansion efforts.

5Notable Q&A Insights

Patient Retention: Retention rates are better than expected, contributing positively to growth; however, the company is monitoring how direct-to-consumer efforts will impact future patient conversions.

Field Expansion Focus: Continued emphasis on expanding the hospital business, with new prescribers and accounts being added consistently.

Market Opportunity Estimates: The potential for subcutaneous ublituximab to nearly double the addressable market for BRIUMVI was discussed, with estimates based on current market dynamics.

Future Guidance: While specific guidance for 2026 was not provided, factors influencing growth include patient persistence, new patient growth, and the effectiveness of marketing strategies. Overall, TG Therapeutics reported a strong quarter with significant revenue growth and strategic advancements, while also acknowledging competitive pressures and cautious optimism regarding future performance.